388108-48-3

Upstream product

• 388108-46-1 (3R,4R)-4-benzyloxycarbonylamino-3-[(S)-3-(4-fluoro-benzyl)-piperidine-1-carbonyl]-piperidine-1-carboxylic acid t-butyl ester 
• 275815-80-0 (S)-3-(4-fluorobenzyl)-piperidine 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 
• 388108-32-5 (3R,4R)-4-((R)-1-phenylethylamino)piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 532977-39-2 4-((R)-1-phenylethylamino)-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 532977-52-9 (3R,4R)-1-(tert-butoxycarbonyl)-4-((R)-1-phenylethylamino)piperidine-3-carboxylic acid 

Downstream Products

• 388108-84-7 (3R,4R)-4-amino-3-[(S)-3-(4-fluoro-benzyl)-piperidin-1-ylmethyl]-piperidine-1-carboxylic acid t-butyl ester 
• 388097-48-1 (3R,4R)-4-[3-(5-acetyl-4-methyl-thiazol-2-yl)-ureido]-3-[(S)-3-(4-fluoro-benzyl)-piperidin-1-ylmethyl]-piperidine-1-carboxylic acid t-butyl ester 

Relevant academic research and scientific papers

CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity

DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid

N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.